Teligent (TLGT) Downgraded by ValuEngine

ValuEngine lowered shares of Teligent (NASDAQ:TLGT) from a buy rating to a hold rating in a report released on Thursday morning, ValuEngine reports.

Separately, Raymond James lowered Teligent from a strong-buy rating to an outperform rating in a research note on Tuesday, March 19th.

Shares of TLGT stock opened at $0.68 on Thursday. The company has a quick ratio of 0.79, a current ratio of 1.46 and a debt-to-equity ratio of 14.43. Teligent has a 52-week low of $0.66 and a 52-week high of $4.52. The stock has a market capitalization of $46.73 million, a PE ratio of -2.06 and a beta of 1.45.

Teligent (NASDAQ:TLGT) last announced its quarterly earnings results on Monday, March 18th. The company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.16). Teligent had a negative net margin of 73.56% and a negative return on equity of 103.41%. The business had revenue of $16.78 million during the quarter, compared to analysts’ expectations of $17.73 million. As a group, equities research analysts expect that Teligent will post -0.17 earnings per share for the current fiscal year.

Several institutional investors have recently made changes to their positions in TLGT. Millennium Management LLC purchased a new position in shares of Teligent in the 4th quarter valued at about $39,000. Paloma Partners Management Co purchased a new position in shares of Teligent in the 4th quarter valued at about $40,000. Raymond James & Associates increased its stake in shares of Teligent by 21.9% in the 4th quarter. Raymond James & Associates now owns 36,700 shares of the company’s stock valued at $50,000 after purchasing an additional 6,600 shares in the last quarter. Raymond James Financial Services Advisors Inc. purchased a new position in shares of Teligent in the 1st quarter valued at about $55,000. Finally, SG Americas Securities LLC purchased a new position in shares of Teligent in the 4th quarter valued at about $60,000. Hedge funds and other institutional investors own 64.59% of the company’s stock.

Teligent Company Profile

Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. It offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.

Featured Story: What is Forex?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.